BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BB-1701 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BB-1701 is under development for the treatment of HER2 positive solid tumors including breast cancer, colon cancer, bladder cancer, gastric cancer, metastatic urothelial carcinoma, non-small cell lung cancer and gastroesophageal junction cancer. It acts by targeting HER2 and is administered by intravenous route.
Bliss Biopharmaceutical (Hangzhou) overview
Bliss Biopharmaceutical (Hangzhou) is a biopharmaceutical company engaged in research, discovery, development and commercialization of anti-tumor macromolecular biotherapeutics and novel drugs for the treatment of various cancer diseases. The company is headquartered in Hangzhou, Zhejiang, China.
For a complete picture of BB-1701’s drug-specific PTSR and LoA scores, buy the report here.